TITLE:
Clinical Experience with Generic Rasagiline (Ralago®) in Patients with Parkinson’s Disease: An Open-Label, Multicenter, Observational Study
AUTHORS:
Dávid Pintér, Júlia Lajtos, József Janszky, Norbert Kovács
KEYWORDS:
Parkinson’s Disease, Rasagiline, Generic Antiparkinsonian Drugs, Health-Related Quality of Life
JOURNAL NAME:
Advances in Parkinson's Disease,
Vol.8 No.2,
May
27,
2019
ABSTRACT: Background: Antiparkinsonian pharmacotherapy represents one of the most important
expenses related to Parkinson’s disease. The
application of generic drugs may help to reduce the economic burden of the
disease; however, efficacy and safety
of these products have been less studied. Objective: To
investigate the efficacy and safety of generic rasagiline (Ralago®) from a clinical perspective. Methods: The Clinical Global Impression of Severity scale was used to rate the
most important motor and non-motor symptoms at baseline and 12 weeks after the
initiation of Ralago®. Patients also identified
symptoms which were the main sources of their
disability and distress in everyday life. Results: A total of 499
patients were enrolled (231 females, mean age: 73.2 ± 9.1 years, mean duration
of disease: 3.6 ± 3.7 years). Of them,
486 patients completed the study protocol. Both motor and non-motor symptoms
showed improvement during 12-week Ralago® treatment. Adverse events were rare, and the
majority of them were not considered
as serious. Conclusions: The generic rasagiline (Ralago®) is an effective and safe generic product.